Lanping Quan
Overview
Explore the profile of Lanping Quan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang W, Xiong H, Zou Y, Xu S, Quan L, Yuan X, et al.
Mol Med Rep
. 2016 Sep;
14(4):3551-8.
PMID: 27599661
Prostate cancer is the fifth most common cause of cancer‑associated mortality for males worldwide. Although dysregulation of the β‑catenin/T‑cell factor (TCF) pathway has been previously reported in prostate cancer, the...
2.
Huang J, Zhou Y, Zhang H, Qu T, Mao Y, Zhu H, et al.
Med Oncol
. 2012 Dec;
30(1):343.
PMID: 23263828
Recurrent or metastatic esophageal cancer has poor prognosis. This study was to assess the efficacy and safety of biweekly paclitaxel and cisplatin combination for patients with recurrent or metastatic esophageal...
3.
Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, et al.
Mol Carcinog
. 2012 Mar;
52(8):634-46.
PMID: 22431000
Emerging evidence has shown the association of aberrantly expressed miR-106a with cancer development, however, little is known about its potential role in gastric carcinogenesis. In our present study, obviously overexpressed...
4.
Zhu H, Wang Q, Hu C, Zhang W, Quan L, Liu M, et al.
Tumour Biol
. 2011 Aug;
32(6):1147-53.
PMID: 21826474
Radiotherapy is one of the main treatments for esophageal squamous cell carcinoma, but there are still no biomarkers to differentiate patients who will benefit from radiation. Although treatment with a...
5.
Liu M, Wang Z, Yang S, Zhang W, He S, Hu C, et al.
Int J Oncol
. 2011 Jan;
38(4):1013-22.
PMID: 21271217
Many studies have demonstrated the overexpression and amplification of the miR-17-92 cluster in malignant human cancers, including B-cell lymphomas and lung cancers. The purpose of this study was to investigate...
6.
Yang S, He S, Zhou X, Liu M, Zhu H, Wang Y, et al.
Exp Mol Med
. 2010 Oct;
42(11):759-67.
PMID: 20890087
The abnormality of serine/threonine kinase Aurora-A is seen in many types of cancers. Although in physiological context it has been shown to play a vital role in cellular mitosis, how...
7.
Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, et al.
Int J Oncol
. 2010 Sep;
37(5):1315-21.
PMID: 20878079
The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and...
8.
Zhang W, Yan S, Liu M, Zhang G, Yang S, He S, et al.
Cancer Lett
. 2010 May;
296(1):113-22.
PMID: 20457486
Epidemiological and experimental studies have indicated selenium could reduce the risk of some cancers. In our present study, growth inhibition and apoptosis were detected upon methylseleninic acid (MSA) treatment in...
9.
Zhu H, Zhang G, Wang Y, Xu N, He S, Zhang W, et al.
Cancer Sci
. 2010 Mar;
101(5):1156-62.
PMID: 20331626
Overexpression of ErbB2 is associated with poor prognosis in breast cancer. Targeting of ErbB2 is a very common therapeutic strategy in ErbB2-overexpressed breast cancer. Herceptin is the first approved and...
10.
He S, Yang S, Deng G, Liu M, Zhu H, Zhang W, et al.
Cell Mol Life Sci
. 2010 Mar;
67(12):2069-76.
PMID: 20300951
Aurora kinase A (AURKA) is an essential mitotic serine/threonine kinase and its abnormal expression is observed in many malignancies, yet the exact role for AURKA in tumorigenesis still remains elusive....